How accurate are certain biomarkers in blood detecting silent heart disease in well controlled diabetes?

B-type natriuretic peptide (BNP) for personalised primary prevention in diabetes: a cross-sectional observational study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN12700399

Enrollment

246

Registered

2015-11-26

Start date

2015-11-18

Completion date

Unknown

Last updated

2020-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus Nutritional, Metabolic, Endocrine Type 2 diabetes mellitus

Interventions

All patients will undergo a blood test followed by a detailed Echo to assess for left ventricular systolic and diastolic function, left atrial size and left ventricular size. Dobutamine stress Echo (D

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 40-85 years 2. Type 2 diabetes with no previous known cardiovascular symptoms or events 3. Clinic blood pressure (BP) or average 24hour BP =140/80mmHg 4. HbA1c value <64 mmol/mol

Exclusion criteria

Exclusion criteria: 1. Clinic BP and average 24hour BP =140/80mmHg 2. Renal impairment (eGFR <60) 3. Atrial fibrillation 4. Significant (defined as more than mild) valvular heart disease either on auscultation or echocardiography 5. Pregnant type 2 diabetics 6. Unable to consent

Design outcomes

Primary

Measure	Time frame
Prevalence of silent heart disease in asymptomatic patients with well-controlled diabetes, assessed with Echo (for left ventricular systolic function, left ventricular diastolic function, left ventricular size, left atrial size) and Dobutamine stress Echo (for inducible ischaemia). This is assessed during participant’s single visit to study centre.	—

Secondary

Measure	Time frame
Accuracy of BNP ± hsTNT as a screening tool for the aforementioned silent heart disease, by assessing correlation of these biomarkers separately and in combination with the silent heart disease. This is further compared with other potential biomarkers in identification of silent heart disease, e.g. uric acid, hs-CRP, neutrophil to lymphocyte count. This is assessed at the end of study, i.e. 18-24 months after commencement of study.	—

Measure

Time frame

Accuracy of BNP ± hsTNT as a screening tool for the aforementioned silent heart disease, by assessing correlation of these biomarkers separately and in combination with the silent heart disease. This is further compared with other potential biomarkers in identification of silent heart disease, e.g. uric acid, hs-CRP, neutrophil to lymphocyte count. This is assessed at the end of study, i.e. 18-24 months after commencement of study.

—

Countries

United Kingdom

Contacts

Public ContactVun Heng Chong

v.h.chong@dundee.ac.uk+44(0)138 238 3346

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026